POP Medical’s NeuGuide surgical system. Photo: courtesy

In January, we reported that the US FDA granted marketing approval to an Israeli minimally invasive system to treat pelvic organ prolapse (POP), which affects half of all women sometime during their life.

POP Medical Solutions developed the NeuGuide solution in response to mounting calls across the world to ban the controversial use of transvaginal mesh to treat the painful and debilitating condition. POP Medical and Escala Medical, another Israeli company developing a minimally invasive POP solution, could revolutionize this $1 billion medical market.